SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a16 OR 15d16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2005
(Translation of registrants name into English)
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F x Form 40-F ¨
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
/s/ Douglas Parkhill
Date: April 15, 2005
|For Immediate Release
|15 April 2005
SkyePharma PLC (the Company)
Notification of Major Interest in Shares
In accordance with the Companies Act 1985 (as amended) the Company was informed on 15th April 2005 that, following a series of market making transactions on 13th April 2005 by Dresdner Kleinwort Wasserstein Securities Limited (DrKWSL), Allianz AG and its subsidiaries, which include DrKWSL, had increased their notifiable interest to 46,875,141 Ordinary Shares, representing 7.5% of the issued share capital of the Company. These Ordinary Shares are registered in the name of DrKWS Nominees Limited.
On 15th April 2005 the company was also informed, in accordance with the Companies Act 1985 (as amended), that following the disposal of 10,668,730 of the Companys Ordinary Shares on 13th and 14th April 2005 Standard Life Investments no longer held a notifiable interest in the Company.
- ends -